[^18F] FLuorthanatrace PET/CT for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is [18F]Fluorthanatrace safe for use in humans?
How is [18F] Fluorthanatrace PET/CT different from other treatments for ovarian cancer?
[18F] Fluorthanatrace PET/CT is unique because it uses a special imaging agent to measure the levels of a protein called PARP-1 in ovarian cancer, helping to predict how well a patient might respond to PARP inhibitors, which are a type of cancer drug. This approach is different from standard imaging techniques, as it provides specific information about the cancer's biology and potential treatment response.14567
Who Is on the Research Team?
Lilie L. Lin
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with solid tumors, such as ovarian, fallopian tube, or primary peritoneal cancer. Participants must have at least one tumor lesion of 1.0 cm visible on standard imaging. Pregnant or breastfeeding women and those unable to tolerate imaging procedures are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive FDG IV and undergo FDG PET/CT scan, followed by fluorine F 18 fluorthanatrace IV and [18F]FTT PET/CT
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- Fluorine F 18 Fluorthanatrace
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator